SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-014126 to GENETIC TECHNOLOGIES LTD (GENE, GNTLF) (CIK 0001166272)

GENETIC TECHNOLOGIES LTD (GENE, GNTLF) (CIK 0001166272)
Date: Dec. 27, 2023 · CIK: 0001166272 · Accession: 0000000000-23-014126

AI Filing Summary & Sentiment

File numbers found in text: 333-276168

Date
December 27, 2023
Author
Not clearly detected
Form
UPLOAD
Company
GENETIC TECHNOLOGIES LTD (GENE, GNTLF) (CIK 0001166272)

Letter

United States securities and exchange commission logo December 27, 2023 Simon Morriss Chief Executive Officer Genetic Technologies Limited 60-66 Hanover Street Fitzroy, Victoria, 3065, Australia Re:Genetic Technologies Limited Registration Statement on Form F-3 Filed December 20, 2023 File No. 333-276168 Dear Simon Morriss: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Darrin M. Ocasio, Esq.

Show Raw Text
United States securities and exchange commission logo
December 27, 2023
Simon Morriss
Chief Executive Officer
Genetic Technologies Limited
60-66 Hanover Street
Fitzroy, Victoria, 3065, Australia
Re:Genetic Technologies Limited
Registration Statement on Form F-3
Filed December 20, 2023
File No. 333-276168
Dear Simon Morriss:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Darrin M. Ocasio, Esq.